MedTrace Logo

Presurgical Trial of Denosumab in Breast Cancer

NCT02900469 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2020-08-21

No results posted yet for this study

Summary

The purpose of this study is to determine whether one dose of denosumab can lead to changes in the tumor, which may decrease the ability of tumor to spread.

Conditions

Interventions

BIOLOGICAL

denosumab

denosumab: 120 mg subcutaneous injection

PROCEDURE

Surgery

Surgery: approximately 2-4 weeks after dosing of denosumab

Sponsors & Collaborators

Principal Investigators

  • Sylvia Adams, MD · NYU Perlmutter Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2019-12-03
Completion
2020-01-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02900469 on ClinicalTrials.gov